Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

James D Chalmers; Mark L Metersky; Joseph Feliciano; Carlos Fernandez; Ariel Teper; Andrea Maes; Mariam Hassan; Anjan Chatterjee

doi:10.1183/23120541.00695-2022

Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

ERJ Open Res. 2023 May 2;9(3):00695-2022. doi: 10.1183/23120541.00695-2022. eCollection 2023 Jul.

Authors

James D Chalmers¹, Mark L Metersky², Joseph Feliciano³, Carlos Fernandez³, Ariel Teper³, Andrea Maes³, Mariam Hassan³, Anjan Chatterjee³

Affiliations

¹ Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
² University of Connecticut School of Medicine, Farmington, CT, USA.
³ Insmed Incorporated, Bridgewater, NJ, USA.

Abstract

Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.